Research Analysts’ Weekly Ratings Updates for Cutera (CUTR)

Several brokerages have updated their recommendations and price targets on shares of Cutera (NASDAQ: CUTR) in the last few weeks:

  • 7/19/2017 – Cutera was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 7/13/2017 – Cutera had its “buy” rating reaffirmed by analysts at Maxim Group. They now have a $33.00 price target on the stock, up previously from $27.00. They wrote, “At the Investor Day on 6/14/17, CUTR reiterated the 2Q17 and full-year 2017 guidance it originally introduced on May 1, 2017. During the Investor Day presentation, CUTR provided additional details on its five-year growth plan, highlighted by its projection of a tripling of its annual revenue to $360M in 2021, from $118M in 2016.””
  • 7/12/2017 – Cutera was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 7/7/2017 – Cutera had its “buy” rating reaffirmed by analysts at Sidoti. They now have a $32.00 price target on the stock, up previously from $30.00.
  • 6/27/2017 – Cutera was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $29.00 price target on the stock. According to Zacks, “Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. “
  • 6/26/2017 – Cutera was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. “
  • 6/26/2017 – Cutera is now covered by analysts at Roth Capital. They set a “buy” rating and a $32.00 price target on the stock.
  • 6/20/2017 – Cutera was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “buy” rating. They now have a $28.00 price target on the stock. According to Zacks, “Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. “
  • 6/3/2017 – Cutera had its “buy” rating reaffirmed by analysts at Sidoti. They now have a $30.00 price target on the stock, up previously from $27.00.

Cutera, Inc. (CUTR) traded down 1.66% during trading on Wednesday, hitting $26.70. 46,101 shares of the stock traded hands. Cutera, Inc. has a 52-week low of $10.43 and a 52-week high of $29.25. The company’s 50 day moving average price is $25.40 and its 200-day moving average price is $21.50. The stock has a market cap of $370.01 million, a P/E ratio of 102.30 and a beta of 0.60.

Cutera (NASDAQ:CUTR) last released its earnings results on Monday, May 1st. The medical device company reported ($0.07) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.07). The company had revenue of $29.30 million for the quarter, compared to analyst estimates of $29 million. Cutera had a net margin of 2.89% and a return on equity of 9.21%. The firm’s quarterly revenue was up 30.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.16) EPS. Equities research analysts forecast that Cutera, Inc. will post $0.46 earnings per share for the current fiscal year.

In related news, CFO Ronald J. Santilli sold 20,856 shares of the stock in a transaction that occurred on Tuesday, May 9th. The shares were sold at an average price of $19.90, for a total transaction of $415,034.40. Following the completion of the sale, the chief financial officer now owns 92,178 shares of the company’s stock, valued at approximately $1,834,342.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Larry Laber sold 1,000 shares of the stock in a transaction that occurred on Wednesday, June 28th. The stock was sold at an average price of $25.88, for a total transaction of $25,880.00. Following the sale, the executive vice president now directly owns 73,140 shares of the company’s stock, valued at approximately $1,892,863.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 146,410 shares of company stock worth $3,119,605. Insiders own 3.30% of the company’s stock.

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Receive News & Ratings for Cutera Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply